LEUKEMIAS

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous therapy, acalabrutinib vs zanubrutinib nuances, and pirtobrutinib's future role.

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Modeling shows zanubrutinib may cut progression and costs versus acalabrutinib in relapsed/refractory CLL, especially in high-risk patients.

Cross-trial analysis shows zanubrutinib delivers longer progression-free survival than ibrutinib or acalabrutinib in relapsed CLL, including high-risk del(17p)/del(11q).

FDA approves 14‑month, all‑oral acalabrutinib plus venetoclax first-line for CLL/SLL, boosting progression-free survival and offering a fixed-duration alternative to chemo.

ASH updates AYA ALL care: pediatric-inspired frontline therapy, MRD-driven decisions, targeted TKIs, and immunotherapy-led relapse treatment.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

G6PD deficiency links to higher remission and longer survival in AML patients on venetoclax plus azacitidine, suggesting a simple biomarker to guide treatment.

CD34+ donor chimerism flags AML relapse early; timely donor lymphocyte infusion boosts MRD-negative remissions and survival after alloHSCT.

Phase 2 data show varnim-cel delivers 83% responses with mostly mild CRS and minimal neurotoxicity, boosting CAR T access in India.

FDA fast-tracks QTX-2101, an oral arsenic trioxide therapy, enhancing treatment accessibility for acute promyelocytic leukemia patients.

FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.

The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.

A long-term study reveals that blinatumomab significantly enhances survival rates in infants with KMT2A-rearranged ALL, offering hope for improved treatment outcomes.

Combination therapies using PD-1/PD-L1 inhibitors enhance survival rates in relapsed/refractory acute lymphoblastic leukemia without added toxicity.

A new study reveals that combining ianalumab with ibrutinib offers promising results for chronic lymphocytic leukemia, enabling some patients to stop therapy.

The FDA designates ICT01 as a breakthrough therapy for unfit AML patients, showcasing promising efficacy in early clinical trials.

New research reveals that ropeginterferon alfa-2b offers no significant benefits over observation after TKI cessation in chronic myeloid leukemia patients.

New research reveals that combining midostaurin with standard chemotherapy significantly improves survival rates and reduces minimal residual disease in AML patients.

A phase 3 study is evaluating olverembatinib with chemotherapy for treating Philadelphia chromosome–positive acute lymphoblastic leukemia, showing promising efficacy and safety.

Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia.

A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.

A phase 1b/2 trial reveals MK-1045 shows manageable safety and promising efficacy in treating relapsed/refractory B-cell acute lymphoblastic leukemia.

Families of children with acute lymphoblastic leukemia face significant financial challenges during treatment, with many experiencing material hardship and income loss.